


MAP3K

MAP kinase kinase kinase, MEKK, MAPKKK

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

MAP3Ks (Mitogen-activated protein kinase kinase kinases), the top components of MAPK cascades, modulate many biological processes, such as growth, development and various environmental stresses. Based on the sequence of their kinase catalytic domain, MAP3Ks are classified into three groups: the MEKK-like, ZIK-like and Raf-like families. Raf-like MAP3Ks constitute largest MAP3K subfamily. Raf-like MAP3Ks play roles in response to biotic and abiotic stresses. MAP3Ks often bind to both MAP4Ks and MAP2Ks in the same pathway. For example, MEKK1 (MAP3K1) binds to both the MAP4K NIK and the MAP2K MKK4, while NSY-1 (MAP3K) binds to the MAP2K SEK-1. MAP3Ks activates MAP2Ks by phosphorylation of a serine and/or threonine, and MAP2Ks activate MAPKs by dual phosphorylation of a Thr-X-Tyr motif.

MAP3K Inhibitors & Modulators

<p>5Z-7-Oxozeanol (FR148083; L783279; LL-Z 1640-2) Cat. No.: HY-12686</p> <p>Bioactivity: 5Z-7-Oxozeanol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC₅₀s of 8 nM and 52 nM, respectively.</p> <p>Purity: 99.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg</p> 	<p>Cot inhibitor-1 Cat. No.: HY-32015</p> <p>Bioactivity: Cot inhibitor-1 is a COT/Tpl2 inhibitor.</p> <p>Purity: 95.25% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>Cot inhibitor-2 Cat. No.: HY-32018</p> <p>Bioactivity: Cot inhibitor-2 is a COT/Tpl2 inhibitor.</p> <p>Purity: 99.20% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>DLK-IN-1 Cat. No.: HY-114331</p> <p>Bioactivity: DLK-IN-1 is a selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12), with a K_i of 3 nM. DLK-IN-1 retains excellent CNS penetration and is well tolerated following multiple days of dosing at concentrations that exceed those required for DLK inhibition in the brain. DLK-IN-1 has... >98%</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>GENE-3511 Cat. No.: HY-12947</p> <p>Bioactivity: GNE-3511 is a dual leucine zipper kinase (DLK) inhibitor with a K_i of 0.5 nM.</p> <p>Purity: 99.98% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>GENE-8505 Cat. No.: HY-114332</p> <p>Bioactivity: GNE-8505 is an orally available inhibitor of Dual leucine zipper kinase (DLK) ^[1].</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg, 250 mg</p> 
<p>GS-444217 Cat. No.: HY-100844</p> <p>Bioactivity: GS-444217 is a potent and selective ATP-competitive inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC₅₀ of 2.87 nM ^[1].</p> <p>Purity: 99.80% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>NG25 Cat. No.: HY-15434</p> <p>Bioactivity: NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC₅₀s of 149 nM and 21.7 nM, respectively.</p> <p>Purity: 99.45% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg</p> 
<p>NQDI-1 Cat. No.: HY-19566</p> <p>Bioactivity: NQDI-1 inhibits apoptosis signal-regulating kinase 1 (ASK1) with a K_i of 500 nM and an IC₅₀ of 3 μM.</p> <p>Purity: 95.93% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Selonsertib (GS-4997) Cat. No.: HY-18938</p> <p>Bioactivity: Selonsertib is an apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC₅₀ of 8.3±0.07.</p> <p>Purity: 99.12% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 

TAK1/MAP4K2 inhibitor 1


Cat. No.: HY-77251

Bioactivity: TAK1/MAP4K2 inhibitor 1 is a potent dual TGF β -activated kinase 1 (**TAK1**) and mitogen-activated protein kinase kinase kinase 2 (**MAP4K2**) inhibitor, with **IC₅₀s** of 41.1 nM and 18.2 nM, respectively.

Purity: 99.70%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



Takinib

Cat. No.: HY-103490

Bioactivity: Takinib is a potent and selective **TAK1** inhibitor with an **IC₅₀** of 9.5 nM.

Purity: 98.00%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg

